The U.S. Food and Drug Administration granted its first-ever emergency use authorization for the gene-editing technology Crispr on Thursday, greenlighting a coronavirus diagnostic test developed by Cambridge, Massachusetts-based Sherlock Biosciences. The test can determine whether a patient sample contains the virus that causes COVID-19 in about an hour.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,